- Home
- AB vs ACLX Comparison
AB vs ACLX Comparison
Compare AB & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AB
- ACLX
- Stock Information
- Founded
- AB 1987
- ACLX 2015
- Country
- AB United States
- ACLX United States
- Employees
- AB N/A
- ACLX N/A
- Industry
- AB Investment Managers
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- AB Finance
- ACLX Health Care
- Exchange
- AB Nasdaq
- ACLX Nasdaq
- Market Cap
- AB 4.5B
- ACLX 4.1B
- IPO Year
- AB 1988
- ACLX 2022
- Fundamental
- Price
- AB $38.81
- ACLX $79.98
- Analyst Decision
- AB Hold
- ACLX Strong Buy
- Analyst Count
- AB 5
- ACLX 12
- Target Price
- AB $39.60
- ACLX $114.75
- AVG Volume (30 Days)
- AB 164.1K
- ACLX 510.9K
- Earning Date
- AB 10-23-2025
- ACLX 11-06-2025
- Dividend Yield
- AB 8.39%
- ACLX N/A
- EPS Growth
- AB 17.05
- ACLX N/A
- EPS
- AB 3.37
- ACLX N/A
- Revenue
- AB N/A
- ACLX $56,979,000.00
- Revenue This Year
- AB N/A
- ACLX N/A
- Revenue Next Year
- AB $9.45
- ACLX $210.71
- P/E Ratio
- AB $11.54
- ACLX N/A
- Revenue Growth
- AB N/A
- ACLX N/A
- 52 Week Low
- AB $32.28
- ACLX $47.86
- 52 Week High
- AB $43.30
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- AB 46.06
- ACLX 67.86
- Support Level
- AB $37.80
- ACLX $73.16
- Resistance Level
- AB $38.53
- ACLX $78.61
- Average True Range (ATR)
- AB 0.63
- ACLX 2.92
- MACD
- AB 0.01
- ACLX 0.70
- Stochastic Oscillator
- AB 54.91
- ACLX 99.12
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.